Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
184 hedge funds and large institutions have $2.05B invested in Medicines Co in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 80 increasing their positions, 42 reducing their positions, and 25 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 42
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more funds holding
Funds holding: 166 → 184 (+18)
8% more capital invested
Capital invested by funds: $1.9B → $2.05B (+$152M)
36% less call options, than puts
Call options by funds: $17.4M | Put options by funds: $27.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Corvex Management
New York
|
+$56.8M |
| 2 |
CI
Cambiar Investors
Denver,
Colorado
|
+$39.1M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$34.1M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$33.1M |
| 5 |
Morgan Stanley
New York
|
+$32.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$72.1M |
| 2 |
BM
Bridger Management
New York
|
-$33.1M |
| 3 |
D.E. Shaw & Co
New York
|
-$28.3M |
| 4 |
PC
PointState Capital
New York
|
-$26.7M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$26.2M |
MDCO Hedge Fund Activity: Q1 2015 in Review
184 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q1 2015, worth a combined $2.05B — up 8% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MDCO positions and 25 closed out — a net gain of 21 holders — while 80 added to existing stakes and 42 trimmed.
The largest buyer was Corvex Management, opening a new position worth an estimated $56.8M. The largest seller was Royce & Associates, cutting an estimated $72.1M.
- 184 institutional investors held Medicines Co (MDCO) as of Q1 2015, up from 166 in Q4 2014.
- Funds reported $2.05B of Medicines Co stock for Q1 2015, up 8% quarter-over-quarter.
- 46 funds opened new Medicines Co positions in Q1 2015 and 25 closed out, a net change of +21 holders.
- The largest Medicines Co buyer in Q1 2015 was Corvex Management, an estimated $56.8M added.
- The largest Medicines Co seller in Q1 2015 was Royce & Associates, an estimated $72.1M sold.
Based on aggregated 13F filings for Q1 2015.